Skip to main content

Advertisement

SpringerLink
Log in

Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia

  • Dementia (KS Marder, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Despite the frequency and importance of dementia associated with Parkinson’s disease (PDD) and dementia with Lewy bodies (DLB), there is relatively little evidence on which to base treatment. Evidence from meta-analysis suggests that rivastigmine can improve cognition and functioning in PDD and also reduce risk of falling. There is also evidence supporting its use in DLB. Recent evidence suggests that memantine may also be effective, particularly for PDD, although evidence is more conflicting. Memantine may also improve parkinsonism and dyskinesias. Few clinical trials of cognition in PD without dementia exist, but there is preliminary evidence for atomoxetine, memantine, and piribedil. There is a lack of systematic evidence for the treatment of visual hallucinations and depression in PDD and DLB. In addition, there is a need for studies of whether potentially disease-modifying agents can prevent or delay the progression to dementia in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.

    Article  PubMed  CAS  Google Scholar 

  2. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005;20:1255–63.

    Article  PubMed  Google Scholar 

  3. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–9.

    Article  PubMed  CAS  Google Scholar 

  4. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67:1931–4.

    Article  PubMed  CAS  Google Scholar 

  5. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 1999;122:1449–68.

    Article  PubMed  Google Scholar 

  6. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–92.

    Article  PubMed  CAS  Google Scholar 

  7. Tiraboschi P, Hansen LA, Alford M, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry. 2002;59:946–51.

    Article  PubMed  Google Scholar 

  8. Meyer PM, Strecker K, Kendziorra K, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry. 2009;66:866–77.

    Article  PubMed  CAS  Google Scholar 

  9. Ray M, Bohr I, McIntosh JM, et al. Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. Neurosci Lett. 2004;372:220–5.

    Article  PubMed  CAS  Google Scholar 

  10. Ballard CG, Court JA, Piggott M, et al. Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn. 2002;11:461–74.

    Article  PubMed  Google Scholar 

  11. Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Beh. 2001;70:571–9.

    Article  CAS  Google Scholar 

  12. • Francis PT. Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. J Neurol. 2009;256 Suppl 3:280–5. This is a scholarly review of the complex and interacting neurochemical changes in PD and their relevance for cognitive and other behavioral changes.

    Article  PubMed  Google Scholar 

  13. Ohara K, Kondo N. Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:311–7.

    Article  PubMed  CAS  Google Scholar 

  14. Sharp SI, Ballard CG, Ziabreva I, et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2008;26:330–8.

    Article  PubMed  CAS  Google Scholar 

  15. Politis M, Wu K, Loane C, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920–7.

    Article  PubMed  CAS  Google Scholar 

  16. Aarsland D, Pahlhagen S, Ballard CG, et al. Depression in Parkinson disease—epidemiology, mechanisms and management. Nat Rev Neurol. 2012;8:35–47.

    Article  CAS  Google Scholar 

  17. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–6.

    Article  PubMed  CAS  Google Scholar 

  18. • Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer disease and associated disorders. Alzheimer Dis Assoc Disord. 2010. doi:10.1097/WAD.0b013e3181e6a4d7. Despite the serotonergic changes associated with DLB, there is little evidence whether serotonergic agents may improve psychiatric or other symptoms. Although a placebo group was not included, this randomized study suggests a less favorable response to citalopram, as well as risperidone, in DLB as compared with AD.

  19. Wesnes KA, McKeith I, Edgar C, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65:1654–6.

    Article  PubMed  CAS  Google Scholar 

  20. Beversdorf DQ, Warner JL, Davis RA, et al. Donepezil in the treatment of dementia with lewy bodies. Am J Geriatr Psychiatry. 2004;12:542–4.

    PubMed  Google Scholar 

  21. • Gustavsson A, Van Der Putt R, Jonsson L, McShane R. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2009;24:1072–8. The authors applied three predictive models to estimate clinical and economic outcomes at 5 years in Alzheimer’s disease and DLB, using data from memory clinic patients. Findings suggest that cholinesterase treatment in DLB is cost saving, comparable to the effect in patients with moderate Alzheimer’s disease.

    Article  PubMed  Google Scholar 

  22. •• Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;3:CD006504. Using Cochrane meta-analysis, this report concludes that cholinesterase inhibitors have a positive impact on global assessment, cognitive function, behavioral disturbance, and activities of daily living rating scale in PDD.

    PubMed  Google Scholar 

  23. • O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:997–1019. The British Association for Psychopharmacology (BAP) revised its first (2006) guidelines for clinical practice with antidementia drugs, concluding that there is type-I evidence for the use of cholinesterase inhibitors for people with PDD and DLB, especially for neuropsychiatric symptoms, and type II evidence that memantine may produce cognitive and global effects.

    Article  PubMed  Google Scholar 

  24. •• Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:613–8. This was the first study suggesting effect of memantine in PDD and DLB, using a parallel-group placebo-controlled design.

    Article  PubMed  CAS  Google Scholar 

  25. • Larsson V, Aarsland D, Ballard C, et al. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry. 2010;25:1030–8. This study presents further data suggesting that memantine can improve REM sleep behavioral disturbance in DLB and PDD patients.

    Article  PubMed  Google Scholar 

  26. • Larsson V, Engedal K, Aarsland D, et al. Quality of life and the effect of memantine in dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2011;32:227–34. In a subsequent analysis of the study, it was shown that the response of memantine on clinical scales translated into meaningful effects of quality of life in DLB and PDD patients.

    Article  PubMed  CAS  Google Scholar 

  27. Johansson C, Ballard C, Hansson O, et al. Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. Int J Geriatr Psychiatry. 2011;26:206–13.

    Article  PubMed  CAS  Google Scholar 

  28. •• Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969–77. In this relatively large multicenter placebo-controlled trial of memantine in PDD and DLB, there were no significant effects in the total patient group, but evidence of effects on clinical global and psychiatric symptoms were reported in DLB patients.

    Article  PubMed  CAS  Google Scholar 

  29. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002;63:513–5.

    Article  PubMed  CAS  Google Scholar 

  30. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13:67–73.

    Article  PubMed  CAS  Google Scholar 

  31. Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356–63.

    Article  PubMed  CAS  Google Scholar 

  32. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633–7.

    Article  PubMed  Google Scholar 

  33. • Lucetti C, Logi C, Del Dotto P, et al. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010;16:522–6. Motor parkinsonian symptoms are common in DLB, but there is little evidence regarding the effect of antiparkinsonian agents. This open-label study followed DLB and PD patients over 1 year and suggests that there is some effect of levodopa in DLB but that the response is smaller and of shorter duration than in PD.

    Article  PubMed  Google Scholar 

  34. • Molloy S, Minett T, O'Brien JT, et al. Levodopa use and sleep in patients with dementia with Lewy bodies. Mov Disord. 2009;24:609–12. The use of levodopa in DLB is hampered by the potential worsening or new emergence of hallucinations and sleep disturbance. This open-label case series suggests that sleep disturbances do not worsen over 6 months levodopa treatment in DLB.

    Article  PubMed  Google Scholar 

  35. Goldman JG, Goetz CG, Brandabur M, et al. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23:2248–50.

    Article  PubMed  Google Scholar 

  36. Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9:56–61.

    Article  PubMed  Google Scholar 

  37. Boot BP, Boeve BF, Roberts RO, et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol. 2012;71:49–56.

    Article  PubMed  Google Scholar 

  38. • Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19:591–6. There is little evidence on which to base treatment of REM sleep behavioral disturbance (RBD), which is common in DLB and PDD. This crossover RCT found positive response of melatonin for RBD in patients with mainly idiopathic RBD, which provides some support for previous case reports of its use in patients with DLB and PDD.

    Article  PubMed  Google Scholar 

  39. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6:85–95.

    PubMed  Google Scholar 

  40. Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med. 2012;226:177–81.

    Article  PubMed  CAS  Google Scholar 

  41. • Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7:639–44A. A pressurized bed alarm customized with a familiar voice to deliver a calming message during vigorous dream-enacting behavior improved symptoms in four consecutive RBD patients who had failed to respond to both clonazepam and melatonin therapy.

    PubMed  Google Scholar 

  42. •• Di Giacopo R, Fasano A, Quaranta D, et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov. Disord. 2012;27:559–61. In this placebo-controlled cross-over trial, rivastigmine lead to a significant reduction in the number of RBD-episodes compared to placebo in 12 PD patients without dementia who had treatment-resistant RBD.

  43. van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. CNS Neurosci Ther. 2011;17:428–41.

    Article  PubMed  Google Scholar 

  44. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New Engl J Med. 2004;351:2509–18.

    Article  PubMed  CAS  Google Scholar 

  45. Schmitt FA, Aarsland D, Bronnick KS, et al. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. Am J Alzheimer's Dis Dement. 2010;25:407–13.

    Article  Google Scholar 

  46. Schmitt FA, Farlow MR, Meng X, et al. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther. 2010;16:330–6.

    Article  PubMed  CAS  Google Scholar 

  47. • Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. Am J Alzheimer's Dis Dement. 2011;26:443–9. This post hoc report of large RCTs with rivastigmine suggests that the pattern of improvement is similar in PDD and Alzheimer’s disease.

    Article  Google Scholar 

  48. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord. 2006;21:456–61.

    Article  PubMed  Google Scholar 

  49. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2006;21:1899–907.

    Article  PubMed  Google Scholar 

  50. Dubois B, Tolosa E, Kulisevsky J, et al. Efficacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia. In: 8th International Conference on Alzheimer's and Parkinson's Diseases 2007; Salzburg, Austria, 2007.

  51. Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf. 2008;31:79–94.

    Article  PubMed  CAS  Google Scholar 

  52. • Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;75:1263–9. In a crossover trial in 23 PD patients without dementia, donepezil reduced the risk of falls by 50 %, as compared with a placebo.

    Article  PubMed  CAS  Google Scholar 

  53. Satoh M, Ishikawa H, Meguro K, et al. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol. 2010;64:337–44.

    Article  PubMed  CAS  Google Scholar 

  54. • Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S42–80. This is a very comprehensive revised version of the evidence-based review of treatments for the nonmotor symptoms of PD, which was first published in 2002.

    Article  PubMed  Google Scholar 

  55. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:31–9.

    Article  PubMed  CAS  Google Scholar 

  56. Holmes AD, Copland DA, Silburn PA, Chenery HJ. Acute nicotine enhances strategy-based semantic processing in Parkinson's disease. Int J Neuropsychopharmacol. 2011;14:877–85.

    Article  PubMed  CAS  Google Scholar 

  57. Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009;72:1121–6.

    Article  PubMed  CAS  Google Scholar 

  58. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958–69.

    Article  PubMed  Google Scholar 

  59. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80:18–23.

    Google Scholar 

  60. • Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord. 2009;24:1217–21. This is one of the first placebo-controlled RCTs of memantine for PDD. No significant difference effect on the primary efficacy outcome was found in this small study.

    Article  PubMed  Google Scholar 

  61. • Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord. 2009;24:277–82. This is the first report suggesting that atomoxetine, a selective noradrenaline uptake inhibitor, may improve cognition in PD.

    Article  PubMed  Google Scholar 

  62. •• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448–55. This is the first placebo-controlled RCT suggesting that atomoxetine, a selective noradrenaline uptake inhibitor, may improve cognition in PD. Cognition was a secondary outcome measure in a study focusing on depression in PD patients without dementia.

    Article  PubMed  CAS  Google Scholar 

  63. Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord. 2006;21:500–9.

    Article  PubMed  Google Scholar 

  64. •• Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011;26:1851–8. This is the first placebo-controlled RCT of the effect of rasagiline, a MAO-B inhibitor, on cognitive impairment in PD. Fifty-five patients with cognitive impairment but without dementia were treated for 3 months, and significant effects were reported on selected tests of executive function and attention.

    Article  PubMed  Google Scholar 

  65. • Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord. 2011;17:156–9. The effect of memantine on a range of nonmotor symptoms was studied in a placebo-controlled RCT in 40 PD patients without dementia. No significant differences were found.

    Article  PubMed  Google Scholar 

  66. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol. 1999;22:273–6.

    PubMed  CAS  Google Scholar 

  67. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on–off" phenomena in Parkinson's disease. Mov Disord. 2010;25:508–10.

    Article  PubMed  Google Scholar 

  68. Litvinenko IV, Odinak MM. Mogil'naya VI, Perstnev SV. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neurosci Behav Physiol. 2010;40:149–55.

    Article  PubMed  CAS  Google Scholar 

  69. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New Engl J Med. 1999;340:757–63.

    Google Scholar 

  70. Corbett A, Ballard C. Antipsychotics and mortality in dementia. Amer J Psychiatry. 2012;169:7–9.

    Article  Google Scholar 

  71. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New Engl J Med. 2009;361:1268–78.

    Article  PubMed  CAS  Google Scholar 

  72. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10:415–23.

    Article  PubMed  CAS  Google Scholar 

  73. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology. 2007;68:1726–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

D. Aarsland: consultancy fees (Lundbeck, Novartis, GSK); C. Ballard: consultancy fees from Lundbeck, Esai, Bristol-Myers Squibb, Janssen, Acadia, and Novartis pharmaceutical companies and speaker fees from Lundbeck, Esai, Bristol-Myers Squibb, Janssen, Acadia, and Novartis pharmaceutical companies; A. Rongve: none; M. Broadstock: none; P. Svenningsson: none.

Author information

Authors and Affiliations

  1. Alzheimer’s Disease Research Centre, Novum, Karolinska Institutet, 141 86, Stockholm, Sweden

    D. Aarsland

  2. Centre for Age-Related Diseases, Stavanger University Hospital, 4000, Stavanger, Norway

    D. Aarsland

  3. Faculty of Medicine, University of Oslo, Oslo, Norway

    D. Aarsland

  4. Department of Old Age Psychiatry and Research, Haugesund Hospital, Psychiatric Clinic, 5504, Haugesund, Norway

    A. Rongve

  5. Age Related Diseases, King’s College London, Wolfson Centre for Age Related Diseases, London, UK

    C. Ballard

  6. Edmond and Lily Safra Research Fellow, King’s College London, Wolfson Centre for Age-Related Diseases, London, UK

    M. Broadstock

  7. Department of Neurology and Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, 17176, Stockholm, Sweden

    P. Svenningsson

Authors
  1. D. Aarsland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Ballard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Rongve
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Broadstock
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Svenningsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Aarsland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aarsland, D., Ballard, C., Rongve, A. et al. Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia. Curr Neurol Neurosci Rep 12, 492–501 (2012). https://doi.org/10.1007/s11910-012-0290-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-012-0290-7

Keywords

Search

Navigation